NCT00352443 - S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

August 31, 2007

Study Completion Date

September 30, 2013

Conditions

LymphomaUnspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

everolimus

part 1: dose assigned by ETx online system PO days 1-28 daily part 2: cohort a: 5 mg PO days 1-28 part 2: cohort a: 1250 mg PO days 8-28 (cycle 1) days 1-28 (subsequent cycles)

DRUG

lapatinib ditosylate

dose assigned by ETx online system PO days 1-28 daily part 2 cohort a: 1250 mg PO d 8-28 (cycle 1) days 1-28 (subsequent cycles) part 2 cohort b: 120 mg PO days 1-28 daily

Trial Locations (6)

80045

University of Colorado Cancer Center at UC Health Sciences Center, Aurora

95817

University of California Davis Cancer Center, Sacramento

90089-9181

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles

40536-0093

Lucille P. Markey Cancer Center at University of Kentucky, Lexington

48109-0942

University of Michigan Comprehensive Cancer Center, Ann Arbor

98195-6043

University Cancer Center at University of Washington Medical Center, Seattle

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

SWOG Cancer Research Network

NETWORK